Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
4.2
Journals
Molecules
Special Issues
Novel Compounds in the Treatment of the CNS Disorders, 2nd...
molecules-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Novel Compounds in the Treatment of the CNS Disorders, 2nd Edition

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 3108

Special Issue Editors

Prof. Dr. Ewa Poleszak

E-Mail Website
Guest Editor
Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland
Interests: depression; anxiety; preclinical study; neuropharmacology; neuropsychopharmacology; toxicological and biochemical analysis
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Anna Serefko

E-Mail Website
Guest Editor
Department of Clinical Pharmacy and Pharmaceutical Care, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland
Interests: depression; anxiety; epilepsy; neuroscience; preclinical studies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Central nervous system (CNS) disorders are a broad group of neurological conditions affecting the functioning of the brain or spinal cord, and in consequence, deteriorating the quality of life of a given patient. Amongst them, bipolar disorder, depression, epilepsy/seizures, migraine, Parkinson's disease, Alzheimer's disease, Huntington's disease, attention deficit/hyperactivity disorder, and multiple sclerosis are most frequently diagnosed. These neurological conditions can be caused by several different factors, such as stroke, trauma, infections, autoimmune disorders, tumors, brain or spinal cord degeneration, structural defects, or genetic determinants. Despite the enormous progress in medicine and pharmacotherapy, the management of CNS diseases is still challenging; most of these disorders cannot be thoroughly cured, not all patients achieve even partial remission, and prescribed drugs induce troublesome side effects. Therefore, continuous attempts have been made to develop new treatment strategies and safer, more effective drugs. Research and medical teams focus on diverse treatment options: innovative compounds, combinations of well-known substances, as well as surgical and neurorehabilitation procedures. In our Special Issue on Novel Compounds in the Treatment of the CNS Disorders, we aim to bring together experts working in the field of neurological conditions and invite them to present their recent results from both pre-clinical and clinical studies related to the pharmacotherapy of CNS disorders. Review articles and short communications on the latest achievements in the management of the CNS disorders are also welcome.

Prof. Dr. Ewa Poleszak
Dr. Anna Serefko
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ADHD
  • autism
  • depression
  • epilepsy
  • neurodegenerative diseases
  • neuroscience
  • preclinical studies
  • clinical studies
  • anxiety
  • schizophrenia

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 2608 KiB  
Article
The Novel Imipramine–Magnesium Complex Exerts Antidepressant-like Activity in Mice Subjected to the Forced Swim Test and the Tail Suspension Test
by Anna Serefko, Joanna Lachowicz-Radulska, Aleksandra Szopa, Mariola Herbet, Agnieszka Czylkowska, Katarzyna Ignatiuk, Anna Dołoto, Bernadeta Szewczyk, Sylwia Wośko, Andrzej Wróbel, Jarosław Szponar, Piotr Wlaź, Piotr Skałecki, Jan Wróbel, Weronika Słotwińska and Ewa Poleszak
Molecules 2025, 30(3), 519; https://doi.org/10.3390/molecules30030519 - 23 Jan 2025
Viewed by 890
Abstract
The objective of this study was to assess the antidepressant efficacy of a novel imipramine–magnesium (IMI–Mg) complex in comparison to the administration of imipramine and magnesium individually. The study utilized adult male albino Swiss mice. Behavioral assessments were conducted using the forced swim [...] Read more.
The objective of this study was to assess the antidepressant efficacy of a novel imipramine–magnesium (IMI–Mg) complex in comparison to the administration of imipramine and magnesium individually. The study utilized adult male albino Swiss mice. Behavioral assessments were conducted using the forced swim test (FST) and the tail suspension test (TST). A locomotor activity test was conducted to exclude false positive results in the FST and TST. Moreover, the study assessed oxidative stress levels in the mice subjected to acute environmental stress by measuring glutathione peroxidase, glutathione reductase, total oxidant status, and total antioxidant status. The administration of the IMI–Mg complex at doses of 5, 10, and 20 mg/kg resulted in a reduction in immobility time in both behavioral tests, thereby indicating the antidepressant-like potential of the tested complex, which was similar to the one observed after the administration of these two compounds as separate drug forms. The efficacy of the novel IMI–Mg complex represents a significant advancement and provides a foundation for future research. This innovative agent has the potential to enhance the safety profile of the therapy, streamline the treatment protocol, improve patient satisfaction, and promote adherence to the therapeutic regimen. Full article
(This article belongs to the Special Issue Novel Compounds in the Treatment of the CNS Disorders, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 1844 KiB  
Review
Future Perspectives of NMDAR in CNS Disorders
by Toni Capó, Joan Biel Rebassa, Iu Raïch, Jaume Lillo, Pau Badia, Gemma Navarro and Irene Reyes-Resina
Molecules 2025, 30(4), 877; https://doi.org/10.3390/molecules30040877 - 14 Feb 2025
Viewed by 1548
Abstract
Neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases are among the leading causes of physical and cognitive disability across the globe. Fifty million people worldwide suffer these diseases, and that number is expected to rise as the population ages. Ictus is another pathology [...] Read more.
Neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases are among the leading causes of physical and cognitive disability across the globe. Fifty million people worldwide suffer these diseases, and that number is expected to rise as the population ages. Ictus is another pathology that also courses with neurodegeneration and is a leading cause of mortality and long-term disability in developed countries. Schizophrenia is not as common as other mental disorders, affecting approximately 24 million people worldwide. All these disorders have in common that still there is not an effective pharmacological treatment to cure them. The N-methyl-D-aspartate (NMDA) receptor (NMDAR) has attracted attention as a potential therapeutic target due to its important role in learning and memory and also due to its implication in excitotoxicity processes. Some drugs targeting NMDARs are already being used to treat symptoms of disorders affecting the central nervous system (CNS). Here, we aim to review the implications of NMDAR in these CNS pathologies, its role as a potential therapeutic target, and the future perspectives for developing new treatments focused on these receptors. Full article
(This article belongs to the Special Issue Novel Compounds in the Treatment of the CNS Disorders, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop